PMID- 37522116
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20230801
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - The global, regional and national burden of type 2 diabetes mellitus in the past, 
      present and future: a systematic analysis of the Global Burden of Disease Study 
      2019.
PG  - 1192629
LID - 10.3389/fendo.2023.1192629 [doi]
LID - 1192629
AB  - AIM: To report the global, regional, and national burden of type 2 diabetes 
      mellitus (T2DM) in 2019, assess its trends in the past, and forecast its trends 
      in the future. METHODS: The main data source was the Global Burden of Disease 
      2019 database. We assessed the changes in T2DM burden from 1990 to 2019 with 
      joinpoint regression analysis. Age-period-cohort analysis was used to forecast 
      the T2DM incidence and mortality rate from 2020 to 2034. RESULTS: The burden of 
      T2DM has increased from 1990 to 2019 generally. The low-middle socio-demographic 
      index (SDI) region had the highest increase in age-standardized incidence rate 
      (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate 
      (ASMR), and age-standardized disability-adjusted life years (ASDR) due to T2DM. 
      Nationally, the increase in ASIR (r=0.151, p=0.046) and the decrease in ASMR 
      (r=0.355, p<0.001) were positively correlated with SDIs. In 2019, the global 
      ASIR, ASPR, ASMR, ASDR due to T2DM were 259.9 (95% UI 240.3-281.4), 5282.9 (95% 
      UI 4853.6-5752.1), 18.5 (95% UI 17.2-19.7), and 801.5 (95% UI 55477000-79005200) 
      per 100,000 population, respectively. Additionally, the ASIR (r=0.153, p=0.030) 
      and ASPR (r=0.159, p=0.024) of T2DM were positively correlated with SDIs, while 
      ASMR (r=-0.226, p=0.001) and ASDR (r=-0.171, p=0.015) due to T2DM were negatively 
      correlated with SDIs. The ASIR was estimated to increase to 284.42, and ASMR was 
      estimated to increase to 19.1 from 2030 to 2034, per 100,000 population. 
      CONCLUSION: Globally, the burden of T2DM has increased in the past and was 
      forecast to continue increasing. Greater investment in T2DM prevention is needed.
CI  - Copyright (c) 2023 Ye, Wu, Yang, Zhu, Chen, Chen, Ji and Hou.
FAU - Ye, Junjun
AU  - Ye J
AD  - Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
AD  - Shantou University Medical College, Shantou, Guangdong, China.
FAU - Wu, Yixi
AU  - Wu Y
AD  - Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of 
      Shantou University Medical College, Shantou, China.
AD  - Shantou University Medical College, Shantou, Guangdong, China.
FAU - Yang, Shuhui
AU  - Yang S
AD  - Department of Endocrine and Metabolic Diseases, Shantou Central Hospital, 
      Shantou, Guangdong, China.
FAU - Zhu, Dan
AU  - Zhu D
AD  - Department of Endocrine and Metabolic Diseases, Shantou Central Hospital, 
      Shantou, Guangdong, China.
FAU - Chen, Fengwu
AU  - Chen F
AD  - Department of Endocrine and Metabolic Diseases, Shantou Central Hospital, 
      Shantou, Guangdong, China.
FAU - Chen, Jingxian
AU  - Chen J
AD  - Shantou University Medical College, Shantou, Guangdong, China.
AD  - Department of Endocrine and Metabolic Diseases, Longhu Hospital, The First 
      Affiliated Hospital of Shantou University Medical College, Shantou, China.
FAU - Ji, Xiaoxia
AU  - Ji X
AD  - Department of Endocrine and Metabolic Diseases, Shantou Central Hospital, 
      Shantou, Guangdong, China.
FAU - Hou, Kaijian
AU  - Hou K
AD  - Department of Endocrine and Metabolic Diseases, Longhu Hospital, The First 
      Affiliated Hospital of Shantou University Medical College, Shantou, China.
AD  - School of Public Health, Shantou University, Shantou, China.
LA  - eng
PT  - Journal Article
DEP - 20230714
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Global Burden of Disease
MH  - Disability-Adjusted Life Years
MH  - Systems Analysis
PMC - PMC10376703
OTO - NOTNLM
OT  - epidemiology
OT  - forecast
OT  - global burden of disease
OT  - trend
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/07/31 06:42
MHDA- 2023/08/01 06:45
PMCR- 2023/01/01
CRDT- 2023/07/31 05:18
PHST- 2023/03/23 00:00 [received]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/08/01 06:45 [medline]
PHST- 2023/07/31 06:42 [pubmed]
PHST- 2023/07/31 05:18 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1192629 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jul 14;14:1192629. doi: 
      10.3389/fendo.2023.1192629. eCollection 2023.